Italy
Every company in the roster headquartered in Italy.
Every company in the roster headquartered in Italy.
7 of 7 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Genenta Science S.p.A.GNTA · Nasdaq | 1 asset: 1 Ph 2 | TemferonPhase 1/2 · Glioblastoma | None on record | —no price since 3 Nov 2026 | $33MDec 2025 | ~17.0 qtrs | $3.1M |
RecordatiREC · Euronext Milan | 4 assets: 3 approved, 1 other | LercanidipineHypertension | None on record | — | — | — | — |
IdB HoldingPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Iperboreal PharmaPrivate | 1 asset: 1 Ph 2 | PolyCorePhase 1/2 · Heart Failure | Dec 2026PolyCore · Phase 1/2 | — | — | — | — |
Istituto Gentili S.R.L.Private | 1 asset: 1 Ph 3 | SugemalimabPhase 3 · Non-Small Cell Lung CancerReliable signal | Dec 2029Sugemalimab · Phase 3 | — | — | — | — |
Kither BiotechPrivate | 1 asset: 1 Ph 2 | KIT2014Phase 1/2 · Chronic Obstructive Pulmonary Disease | 31 Mar 2027KIT2014 · Phase 1/2 | — | — | — | — |
Nerviano Medical SciencesPrivate | 1 asset: 1 Ph 1 | NMS-03597812Phase 1 · Acute Myeloid Leukemia | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.